Fasting and Diabetes During Ramadan

Overview of Ramadan Fasting Among Muslims with Diabetes

Many Muslims with diabetes choose to participate in Ramadan fasting, often despite medical advice. To assist healthcare professionals in guiding their patients, the International Diabetes Federation (IDF) and the Diabetes and Ramadan (DAR) International Alliance have established Practical Guidelines. These guidelines aim to enhance the understanding of diabetes management during Ramadan.

Challenges of Fasting for Diabetic Individuals

Research indicates that a significant number of diabetes patients fast for at least 15 days during Ramadan. The altered meal timings and sleep patterns during this month can disrupt homeostatic and endocrine functions in the body.

For those with Type 1 or Type 2 Diabetes Mellitus (T1DM or T2DM), fasting can lead to the breakdown of glycogen into glucose and the synthesis of glycogen from non-carbohydrate sources. Type 1 diabetics, in particular, may produce ketone bodies through the breakdown of fatty acids and certain amino acids. These metabolic processes increase the risk of low blood sugar (hypoglycemia), high blood sugar (hyperglycemia), and elevated ketone levels (diabetic ketoacidosis). Several studies suggest that these risks are heightened during Ramadan fasting.

While healthy individuals generally maintain stable glucose levels before and during Ramadan, diabetic patients exhibit significant individual variability, warranting a personalized approach to diabetes management.

Risk Categories for Diabetic Patients During Ramadan

The IDF and DAR International Alliance, consisting of diabetes experts, have created practical guidelines for managing diabetes during Ramadan. Their findings are published in a recent edition of Diabetes Research and Clinical Practice. The study synthesizes results from various clinical studies and expert opinions to offer recommendations for fasting patients.

The Alliance has classified patients into three risk categories based on current scientific and clinical information:

1. **Very High Risk**: This category includes patients who have experienced severe hypoglycemia, unexplained diabetic ketoacidosis, or hyperosmolar hyperglycemic coma in the three months preceding Ramadan. It also encompasses those with a history of recurrent hypoglycemia, severe medical conditions, and pregnant women with pre-existing diabetes. Patients in this group should not fast; if they choose to do so, close monitoring by qualified professionals is essential, and they should be prepared to break their fast if necessary.

2. **High Risk**: This group consists of patients with well-controlled T1DM and T2DM who have stable medical conditions. Individuals in this category are advised against fasting.

3. **Moderate or Low Risk**: This category includes individuals with well-managed T2DM through lifestyle changes and/or medication. Those in this group may consider fasting but should consult a healthcare provider beforehand.

For patients in any of these categories who choose to fast, structured education, regular blood glucose monitoring, and adjustments to their medication dosages are recommended.

Guidelines and Recommendations for Healthcare Providers

The IDF-DAR guidelines provide up-to-date advice for healthcare providers and patients regarding fasting during Ramadan according to risk category. For patients who opt to fast against medical advice, a personalized management plan is advisable. While these guidelines have been endorsed by high-ranking religious authorities in Egypt, opinions differ in other regions, highlighting the need for further dialogue and collaboration between religious leaders and healthcare providers.

Reference

Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, Hanif W, Lessan N, Basit A, Tayeb K, Omar M, Abdallah K, Al Twaim A, Buyukbese A, El-Sayed AA, Ben-Nakhi A, On behalf of the International Diabetes Federation (IDF), in collaboration with the Diabetes and Ramadan (DAR) International Alliance. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017 Apr;126:303-316. doi: 10.1016/j.diabres.2017.03.003

Written By: Asongna T. Folefoc